ClinicalTrials.gg
CompletedNCT04179643NAN-CS101Updated Aug 6, 2026

AB-1002 in Patients With Class III Heart Failure

A Phase 1 interventional study of 3 x 10e13vg AB-1002 in Congestive Heart Failure, Heart Failure and Heart Disease, Ischemic, sponsored by AskBio Inc. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-06.

Sponsored by AskBio Inc (part of Bayer) · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Aug 2024, 2 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
11
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 47 studies in Heart Failure by Bayer — 6 open to participants now, 7 under way, 2 of them phase 3. Heart Failure · Bayer.

Enrollment
31st of 33
11 · median 62
Started
2019
with 2 others
Phase 1
10 of 47
none open now
Registered
21st of 47
by date

Among the 47 studies in Heart Failure by Bayer, this one is the 31st largest by enrollment of the 33 interventional ones that give a count, is one of 3 that started in 2019, is one of 10 in phase 1, and was the 21st registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

6 of the 47 studies in Heart Failure by Bayer are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Heart Failure by Bayer, or all of them as a file.
02

Study summary

This is a Phase 1, prospective, multi-center, open-label, sequential dose escalation study to explore the safety, feasibility, and efficacy of a single intracoronary infusion of AB-1002 in patients with NYHA Class III heart failure. 11 participants with non-ischemic cardiomyopathy were enrolled. All participants were followed until 12 months post treatment intervention, and then underwent long-term follow-up via semi-structured telephone questionnaires every 6 months for an additional 24 months (+/- 30 days).

Read the detailed description

The safety endpoints will be assessed over the 12-month follow-up period

  • Adverse Events
  • Clinical laboratory tests
  • Vital signs
  • Electrocardiograms

Efficacy Endpoints

The efficacy endpoints assessed from baseline to 6 and 12 months will include the following:

  • Observed and changes from baseline in peak VO2 assessed by cardiopulmonary exercise testing
  • Observed and changes from baseline in 6-minute walk test
  • Observed and changes from baseline in NYHA Classification
  • Total number of days alive out-of-hospital

The secondary efficacy endpoints will explore efficacy. Functional endpoints will be assessed as changes from baseline to 6 and 12 months following investigational product administration as indicated. These endpoints include:

Functional Status \& Hospitalizations

  • Peak VO2 assessed by cardiopulmonary exercise testing
  • 6-minute walk test
  • New York Heart Association (NYHA) Classification
  • Total number of days alive out-of-hospital (as well as total days out-of-hospital as a % of total days alive post study intervention)

Physiologic Assessments at 6 and 12 months compared to baseline

  • Echocardiographic assessments of LVEF, LVEVD, LVEDVI, VLESV, LVEVI, SpI and GLSand degree of mitral regurgitation
  • NT-proBNP level

Quality of Life at Week 8, 6 and 12 months compared to baseline

o Health related quality of life as assessed by Minnesota Living with Heart Failure Questionnaire (MLWHFQ) and Kansas City Cardiomyopathy Questionnaire

The following endpoints will also be measured over the 12 month follow-up period and long-term follow-up period (until month 36 post-intervention):

  • Survival
  • Cardiac transplantation
  • Left ventricular assist device (LVAD) implantation
03

Conditions studied

  • Congestive Heart Failure
  • Heart Failure
  • Heart Disease, Ischemic
  • Cardiovascular Diseases
  • Heart Failure, Systolic
  • Heart Failure,Congestive
  • Heart Arrhythmia
  • Heart Failure, Diastolic
  • Heart; Complications
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >18 years of age
  • Chronic non-ischemic cardiomyopathy
  • 15% ≤ 30% by transthoracic echocardiography (TTE) within 6 months prior to enrollment
  • Class III HF for a minimum of 3 months HF despite appropriate medical therapy (defined below):

    • Treatment with appropriate HF therapy as tolerated, including, but not limited to:
    • Beta blocker therapy and angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) or sacubitril/valsartan combination therapy (Entresto) for ≥ 90 days prior to enrollment. May also receive aldosterone antagonist therapy. Doses of the above medications must be stable for ≥ 30 days prior to enrollment; and
    • Cardiac resynchronization therapy (CRT), if clinically indicated, must have been implanted ≥ 90 days prior to enrollment. Internal cardioverter defibrillator (ICD) must be implanted, if clinically indicated ≥ 30 days prior to enrollment
  • Females of must use at least one of the following acceptable methods throughout the study and for 6 months after IP administration:
  • Surgically sterile (bilateral tubal ligation, hysterectomy, bilateral oophorectomy) 6 months minimum prior to IP administration
  • Intrauterine device in place for at least 90 days prior to receiving IP
  • Barrier methods (diaphragm plus spermicide or condom) starting at least 30 days prior to receiving IP
  • Abstinence (the subject must be willing to remain abstinent from screening to 6 months after receiving IP). Females are allowed to claim abstinence as their method of contraception only when it is the preferred and usual lifestyle of the subject
  • Surgical sterilization of the partner(s) (vasectomy) for >180 days prior to IP administration
  • Hormonal contraceptives starting > 90 days prior to IP. If hormonal contraceptives are started less than 90 days prior to receiving IP, subjects must agree to use a barrier method (diaphragm plus spermicide or condom) from screening through 90 days after initiation of hormonal contraceptives
  • Males subjects capable of fathering a child:
  • Must agree to use a condom from IP administration through 6 months after the time of IP administration
  • Must agree not to donate sperm for 6 months after time of receiving IP
  • Documented evidence of vasectomy in males for 180 days minimum prior to receiving IP is an acceptable form of contraception
  • Males who claim abstinence as their method of contraception are allowed provided they agree to use barrier methods should they become sexually active from screening through 6 months after receiving IP. Males are allowed to claim abstinence as their method of contraception only when it is the preferred and usual lifestyle of the subject
  • Ability to sign Form (ICF) and Release of Medical Information Form
  • Appropriate candidate for protocol-specified intracoronary infusion in the judgment of the infusing interventional cardiologist

Cohort 3: medical history documentation of PLN-R14Del mutation and an ICD in situ (at least 30 days prior to enrollment)

Exclusion criteria

Exclusion Criteria:

  • Chronic ischemic cardiomyopathy
  • Intravenous (IV) inotropic therapy, intra-aortic balloon pump (IABP) or percutaneous cardiac assist device therapy within 30 days prior to enrollment
  • Restrictive cardiomyopathy, obstructive cardiomyopathy, pericardial disease, amyloidosis, infiltrative cardiomyopathy, uncorrected thyroid disease, or dyskinetic LV aneurysm
  • Cardiac surgery or percutaneous coronary intervention (PCI) within 30 days prior to enrollment
  • Third degree heart block
  • myocardial infarction (MI) in the judgment of the subject's physician (e.g., ST elevation MI [STEMI] or large non-STEMI) within 6 months prior to enrollment
  • Prior heart transplantation, left ventricular reduction surgery (LVRS), cardiomyoplasty, passive restraint device (e.g., CorCap™ Cardiac Support Device), surgically implanted LVAD or cardiac shunt
  • Likely to receive cardiac resynchronization therapy, cardiomyoplasty, LV reduction surgery, heart transplant, conventional revascularization procedure, or valvular repair within 3 months of IP dosing
  • Known to contrast dyes used for angiography; history of, or likely need for, high-dose pretreatment prior to contrast angiography
  • Expected survival \< 1 year in the judgment of the investigator
  • Active or suspected infection within 48 hours prior to enrollment as evidenced by fever or positive culture
  • Known intrinsic liver disease (e.g., cirrhosis, hepatitis A, chronic or virus infection). If serology is positive and PCR is negative, subject may be eligible (confirm with medical monitor).
  • Liver function tests ( [ALT], aspartate aminotransferase [AST], alkaline phosphatase) > 2x (ULN) within 30 days prior to enrollment.
  • Renal Failure, dialysis dependent or serum creatinine > 2.5 mg/dl within 30 days prior to enrollment
  • Bleeding diathesis or thrombocytopenia defined as \<50,000 platelets/μL within 30 days prior to enrollment
  • Anemia defined as \<10 g/dL or transfusion dependent within 30 days prior to enrollment
  • Neutropenia defined as absolute neutrophils \<1500 mm3 within 30 days prior to enrollment
  • Known AIDS or -positive status, or a previous diagnosis of immunodeficiency with an \<1000 cells/mm3
  • Previous participation in a study of gene transfer
  • Receiving intervention or participating in another clinical study within 30 days or within 5 half-lives of another investigational drug administration prior to administration of NAN-101 that may impact the therapeutic potential of NAN-101.
  • Pregnancy or breastfeeding at the time of screening
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    3.25E13vg AB-1002

    Intracoronary Infusion of 3.25E13vg AB-1002 up to 6 subjects

    Biological: 3 x 10e13vg AB-1002

  • Experimental
    1.08E14vg AB-1002

    Intracoronary Infusion of 1.08E14vg AB-1002 to 6 subjects

    Biological: 3 x 10e13vg AB-1002

  • Experimental
    PLN-R14Del patients: 3.25E13vg AB-1002

    Intracoronary Infusion of AB-1002 at 3.25E13vg up to 6 subjects with PLN-R14Del genetic mutation

    Biological: 3 x 10e13vg AB-1002

Interventions

  • Biological3 x 10e13vg AB-1002

    There are 2 components to AB-1002. The first is an active I-1 transgene (AA 1-65 with T35D), and the second is the vector, BNP116, which delivers the gene selectively to the heart after intracoronary administration.

06

What researchers measure

Primary outcomes

  1. Observed and change from baseline in Peak VO2

    Cardiopulmonary exercise testing using a modified Bruce protocol

    Time frame: Measured at screening, month 6, 9 and month 12

  2. Observed and change from baseline in Echocardiographic assessment in Left Ventricular Ejection Fraction

    Echocardiography LVEF measurement

    Time frame: Measured at screening, 18-24 hours post intervention, week 4, Month 3, Month 6 and Month 12

Secondary outcomes

  1. Observed and change from baseline in 6-minute walk test distance

    Analysis of Percent predicted in heart failure subjects compared to normal subjects

    Time frame: Measured at screening, Month 3, Month 6 and month 12

07

Study locations

4 sites
  • Minneapolis Heart Foundation Institute
    Minneapolis, Minnesota 55407, United States
  • The Linder Center for Education and Research at The Christ Hospital
    Cincinnati, Ohio 45219, United States
  • The Ohio State University
    Columbus, Ohio 43210, United States
  • University of Wisconsin at Madison
    Madison, Wisconsin 53792, United States
08

References and documents

Publications

  • Henry TD, Chung ES, Alvisi M, Sethna F, Murray DR, Traverse JH, Roessig L, Roberts L, Reddy S, Chen Y, Ozkan TG, Webb S, Mittal M, Ervin L, Sadek H, Mikhail S, Haghighi K, Jiang C, Samulski RJ, Kranias EG, Tretiakova AP, Hajjar RJ. Cardiotropic AAV gene therapy for heart failure: a phase 1 trial. Nat Med. 2025 Nov;31(11):3845-3852. doi: 10.1038/s41591-025-04011-z. Epub 2025 Oct 21. PubMed 41120766 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2019 to primary completion in Aug 2024, 57 months.

Of 77 industry-sponsored phase 1 interventional studies under Heart Failure, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 16. This study's 57 months is above that.

Counting every sponsor, half of 131 studies reached it within 14 months; a quarter within 4 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2019
First posted
Nov 27, 2019
StartActual
Nov 20, 2019
Primary completionActual
Aug 20, 2024
CompletionActual
Jul 23, 2026
Last update
Aug 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04179643
Lead sponsor
AskBio Inc
Responsible party
Sponsor
First posted
Nov 27, 2019
Start date
Nov 20, 2019
Primary completion
Aug 20, 2024
Completion
Jul 23, 2026
Last update
Aug 6, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion